Brief Summary
The aim of this study is to assess the progression free survival (PFS) of SABR alone and SABR + 177Lu-prostate-specific membrane antigen (PSMA) in patients with oligometastatic prostatea walnut-shaped gland in the male reproductive system that is responsible for producing semen - a bodily fluid that acts as a vessel for sperm transport during ejaculation cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs undergoing PSMA positron emission tomography (PET) stagingthe process of determining how big the cancer is, where it started and if it has spread to other areas.
Intervention / Treatment
- Drug: 177Lu-PSMA
Inclusion Criteria:
- Male aged 18 years or older at screeningtesting for cancer or conditions that can lead to cancer before symptoms appear, also known as cancer screening
- Patient has provided written informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment.
- Histologically confirmed prostate adenocarcinomacancer arising from mucus-producing glands in organs w
- Prior definitive treatment of the primary with either curative intent radiotherapy and/or surgerytreatment involving removal of cancerous tissue and/or tumours and a margin of healthy tissue around it to reduce recurrence
- Patient has 1-5 sites of nodal or bony metastases on 68Ga-PSMA or 18F-DCFPyL PET/CT with a score of 4 or 5 as defined by the E-PSMA criteria
- At least one site of disease with SUVmax greater than the SUVmax of liver on PSMA PET (Ga-68 PSMA 11 or F-18 DCFPYL tracers only)
- Adequate haematological function as defined by:
- Absolute neutrophil count (ANC) ≥1.5 x 109/L
- Platelet count >150x 109/L
- Haemoglobin ≥100 g/L
- Creatinine Clearance ≥ 40mL/min (Cockcroft-Gault formula)
- Assessed as suitable for SABR by a radiation oncologista doctor who specialises in treating cancer with radiation therapy
- Patients must agree to use an adequate method of contraception
- Have a performance status of 0-1 on the ECOG Performance Scale